| Biological Sciences | Lifetime | 419 | US 246 | 99.95 |
| Medical and Health Sciences | 2021-2025 | 643 | US 219 | 99.86 |
| Biological Sciences | 2021-2025 | 406 | US 88 | 99.57 |
| Immunology | Lifetime | 49 | US 32 | 99.92 |
| Molecular Biology | Lifetime | 387 | US 246 | 99.82 |
| Infectious Diseases | Lifetime | 133 | US 66 | 99.58 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 433 | US 250 | 98.93 |
| Epidemiology | Lifetime | 847 | US 427 | 98.86 |
| Virology | Lifetime | 222 | US 139 | 95.74 |
| Microbiology | Lifetime | 582 | US 259 | 84.51 |
| Immunology and Allergy | Lifetime | 740 | US 302 | 83.70 |
| Infectious Diseases | 2021-2025 | 2 | US 1 | 99.92 |
| Immunology | 2021-2025 | 77 | US 25 | 98.54 |
| Molecular Biology | 2021-2025 | 253 | US 66 | 98.88 |
| Clinical Neurology | 2021-2025 | 165 | US 61 | 95.95 |
| COVID-19 Clinical Research Studies | Lifetime | 3 | US 1 | 99.96 |
| Immunotherapy and Immune Responses | Lifetime | 6 | US 4 | 99.98 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 5 | US 2 | 99.95 |
| vaccines and immunoinformatics approaches | Lifetime | 2 | US 2 | 99.96 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 23 | US 17 | 99.92 |
| T-cell and B-cell Immunology | Lifetime | 38 | US 28 | 99.91 |
| Immune Cell Function and Interaction | Lifetime | 88 | US 59 | 99.86 |
| Long-Term Effects of COVID-19 | Lifetime | 32 | US 10 | 99.41 |
| Hepatitis B Virus Studies | Lifetime | 242 | US 84 | 99.26 |
| HIV Research and Treatment | Lifetime | 496 | US 304 | 98.72 |
| Poxvirus research and outbreaks | Lifetime | 90 | US 58 | 97.61 |
| Herpesvirus Infections and Treatments | Lifetime | 674 | US 387 | 97.05 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 857 | US 351 | 96.78 |
| Cytomegalovirus and herpesvirus research | Lifetime | 990 | US 527 | 96.51 |
| Immune responses and vaccinations | Lifetime | 132 | US 36 | 95.25 |
| Viral Infections and Outbreaks Research | Lifetime | 661 | US 316 | 94.66 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 1 | US 1 | 99.97 |
| COVID-19 Clinical Research Studies | 2021-2025 | 2 | US 1 | 99.97 |
| Immunotherapy and Immune Responses | 2021-2025 | 5 | US 2 | 99.76 |
| vaccines and immunoinformatics approaches | 2021-2025 | 1 | US 1 | 99.81 |
| Long-Term Effects of COVID-19 | 2021-2025 | 31 | US 8 | 99.33 |
| T-cell and B-cell Immunology | 2021-2025 | 35 | US 22 | 98.46 |
| Immune responses and vaccinations | 2021-2025 | 9 | US 4 | 98.32 |
| Nuclear Receptors and Signaling | 2021-2025 | 16 | US 5 | 94.44 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 221 | US 69 | 95.92 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 653 | US 211 | 91.33 |
| Herpesvirus Infections and Treatments | 2021-2025 | 475 | US 153 | 85.06 |
| Bacterial Infections and Vaccines | 2021-2025 | 383 | US 89 | 83.12 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 710 | US 278 | 80.88 |
| Poxvirus research and outbreaks | 2021-2025 | 387 | US 84 | 79.74 |
| Bacillus and Francisella bacterial research | 2021-2025 | 739 | US 183 | 67.99 |
| Insects and Parasite Interactions | 2021-2025 | 308 | US 79 | 49.92 |
